Assignee
REGENACY PHARMACEUTICALS LLC
US·12 granted patents·5 pending applications·14 citations·filing 2016–2023
Top patents by PatentIndex Score
17 records- 0193US10239837B2Piperidine derivatives as HDAC1/2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2017·Granted Mar 26, 2019·4 cites·5 claims
- 0287US10858323B2HDAC inhibitors for the treatment of diabetic peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2018·Granted Dec 8, 2020·5 cites·4 claims
- 0387US10358421B2Piperidine derivatives as HDAC1/2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2017·Granted Jul 23, 2019·2 cites·17 claims
- 0484US2023348389A1Piperidine derivatives as hdac1/2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 0579US10774056B2Substituted piperazines as selective HDAC1,2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2019·Granted Sep 15, 2020·1 cites·4 claims
- 0675US11702389B2Piperidine derivatives as HDAC1/2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2021·Granted Jul 18, 2023·0 cites·19 claims
- 0775US10125131B2Selective HDAC3 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2016·Granted Nov 13, 2018·1 cites·23 claims
- 0873US10968180B2Piperidine derivatives as HDAC1/2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2019·Granted Apr 6, 2021·0 cites·7 claims
- 0971US10272084B2Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2016·Granted Apr 30, 2019·1 cites·6 claims
- 1066US10385031B2Substituted piperazines as selective HDAC1,2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2017·Granted Aug 20, 2019·0 cites·18 claims
- 1165US11013740B2Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2019·Granted May 25, 2021·0 cites·5 claims
- 1265US9957259B2Selective HDAC1 and HDAC2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2017·Granted May 1, 2018·0 cites·11 claims
- 1360US2021251990A1Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral NeuropathyREGENACY PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 1460US2021155593A1Hdac inhibitors for the treatment of diabetic peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 1559US11858919B2HDAC1,2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2019·Granted Jan 2, 2024·0 cites·16 claims
- 1646US2021332036A1Pyrimidine and pyrazine hdac1,2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2019·Application pending·0 cites
- 1735US2017240535A1Hdac1/2 inhibitors for the treatment of neurodegenerative and/or cognitive disordersREGENACY PHARMACEUTICALS LLC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when REGENACY PHARMACEUTICALS LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →